Zentalis Pharmaceuticals (ZNTL) said late Tuesday it will reduce its workforce by about 40% to focus on advancing the late-stage development of its experimental cancer therapy, azenosertib.

The company said the restructuring will extend its cash runway beyond the anticipated data readout from a potentially registration-enabling azenosertib study, expected by the end of 2026.

The workforce reduction is set to be substantially completed in Q2.